Galecto (GLTO)

• Market cap: $5.23M
• 1 day: -1.98%
• 5 days: -4.11%
• 1 month: -13.32%
• 3 months: -21.85%
• 6 months: -69.30%
• Year to date: -30.35%
• 1 year: -78.86%
• 5 years: -98.94%
• 10 years: -98.94%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.

Employees: 13

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

50% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 2

11% more funds holding

Funds holding: 9 [Q3] → 10 (+1) [Q4]

0.47% more ownership

Funds ownership: 10.29% [Q3] → 10.76% (+0.47%) [Q4]

0% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 2

58% less capital invested

Capital invested by funds: $1.56M [Q3] → $661K (-$902K) [Q4]